| Special Symposium-1 “Global perspectives on diabetes management” |
| May 22 (Thu.) 15:00-17:30 Room 1, Hall A |
| SS 1-1 |
The Need for Coordinated Global Responses to the Diabetes Epidemic |
International Diabetes Federation, Australia
Martin Silink |
| SS 1-2 |
A1C or Average Blood Glucose : Evidence from the ADAG Study |
Endocrinology and Diabetic Medicine, Biomedical Sciences, University of Yaoundé I,
Yaoundé, Cameroon, International Diabetes Federation
Jean Claude Mbanya |
| SS 1-3 |
|
International Diabetes Federation, Italy
Massimo Massi-Benedetti |
| SS 1-4 |
Awareness and Advocacy Following the United Nations Declaration on Diabetes |
International Diabetes Federation, Canada
Brian K. Wentzell |
| SS 1-5 |
|
| SS 1-6 |
|
|
| Special Symposium-2 “Controversies in Diabetes” |
| May 23 (Fri.) 9:00-11:30 Room 1, Hall A |
| SS 2-1 |
When Does One Get Diabetes？ Elevation of Plasma Glucose or Cardiovascular Risk？ |
Aino Institute for Aging Research, Japan
Takeshi Kuzuya |
| SS 2-2 |
Metabolic Syndrome as a Clinical Entity |
Kansai Electric Power Hospital, Japan
Yutaka Seino |
| SS 2-3 |
|
Department of Public Health, University of Helsinki, Finland
Jaakko Tuomilehto |
| SS 2-4 |
Prevention of Diabetic Microangiopathy : The Role of Renin Angiotensin System Blockade |
Sinai Centre for Diabetes, University of Toronto, Canada
Bernard Zinman |
| Summary |
International Diabetes Institute, Australia
Paul Zimmet |
|
| Special Symposium-3 “Diabetes susceptibility genes now becoming unraveled” |
| May 23 (Fri.) 15:00-17:30 Room 1, Hall A |
| SS 3-1 |
Lessons from Human Phenotypes of Obesity and Insulin Resistance |
Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
S. O’Rahilly |
| SS 3-2 |
Genes Influencing Type 2 Diabetes and Related Traits : Discovery and Application |
The University of Oxford, The Oxford Radcliffe Hospitals Trust, UK
Mark McCarthy |
| SS 3-3 |
Both GWAs for Quantitative Phenotypes and for Severe Obesity/T2D Provide Breakthroughs in Glucose and Energy Homeostasis |
Genomic Medicine, Hammersmith Hospital, Imperial College London, UK,
Institute of Biology, Pasteur Institute, Lille, France
Philippe Froguel |
| SS 3-4 |
Genetics of Type 2 Diabetes is About More Than Genes-Also Epigenetics, Environment and Interactions |
Lund University Diabetes Centre, Malmö, Sweden
Leif Groop |
| SS 3-5 |
|
Department of Internal Medicine, Division of Endocrinology, Metabolism, Pathobiochemistry, and Clinical Chemistry,University of Tübingen, Germany
Hans-Ulrich Häring |
| SS 3-6 |
|
| SS 3-7 |
|
|
| Special Symposium-4 “Global trends in diabetes education : From instructions on diabetes care to tips on patient empowerment” |
| May 24 (Sat.) 9:00-11:30 Room 1, Hall A |
| SS 4-1 |
|
| SS 4-2 |
A Global Response to the Evolving Dynamic of Diabetes Self-Management |
University of Pittsburgh, Diabetes Institute, Pittsburgh, USA
Linda Siminerio |
| SS 4-3 |
Empowerment : You Talk the Talk, but Do You Walk the Walk？ |
University of Michigan, Ann Arbor Michigan, USA
Robert M. Anderson |
| SS 4-4 |
The Art and Science of Diabetes Education |
School of Child & Adolescent Health, University of Cape Town, South Africa
Areti Philotheou |
| SS 4-5 |
|
|
| Symposium-1 “Large-scale clinical studies in Japan and abroad” |
| May 22 (Thu.) 15:00-17:30 Room 2, Hall C |
| S 1-1 |
The Role of Incretion Hormones in Type 2 Diabetes |
Division of Metabolism, Endocrinology and Nutrition, Department of Medicine,
VA Puget Sound Health Care System and University of Washington, USA
Steven E. Kahn |
| S 1-2 |
|
| S 1-3 |
Multifactorial Intervention to Prevent Mortality and Cardiovascular Complications in Patients with Type 2 Diabetes |
Department of Endocrinolgy, Copenhagen University Hospital Herlev, Denmark
Peter Gaede |
| S 1-4 |
Pioglitazone to Prevent Macrovascular Events in Patients with Type 2 Diabetes :
the PROactive Study |
Department of Cardiovascular Medicine, University Hospital, Nottingham, UK
Robert G. Wilcox |
| S 1-5 |
J-DOITs Currently Ongoing in Japan as the Strategic Research for the Prevention of Type 2 Diabetes and its Complications |
Department of Diabetes and Metabolic Medicine, International Medical Center of Japan
Mitsuhiko Noda |
| S 1-6 |
The DREAM Study |
Diabetes Trials Unit, OCDEM, University of Oxford, UK
Rury Holman |
|
| Symposium-2 “Pathogenesis of type 2 diabetes as a consequence of pancreatic β cell mass modulation” |
| May 22 (Thu.) 15:00-17:30 Room 3, Hall B 7-1 |
| S 2-1 |
Growth Factor Signaling and the Regulation of Beta Cell Mass and Function |
Joslin Diabetes Center, Harvard Medical School, USA
Rohit N. Kulkarni |
| S 2-2 |
Epigenetic Regulation of Pathological and Physiological Growth in Pancreatic Islets |
Department of Developmental Biology, Department of Medicine（Oncology Division）Stanford University, USA
Seung K. Kim |
| S 2-3 |
|
| S 2-4 |
|
| S 2-5 |
|
| S 2-6 |
|
|
| Symposium-3 “Cutting-edge research in diabetic nephropathy” |
| May 22 (Thu.) 15:00-17:30 Room 4, Hall B 7-2 |
| S 3-1 |
Nephropathy and the Renin-angiotensin System : Recent Developments |
University of Toronto, St. Michael’s Hospital, Canada
Richard E. Gilbert |
| S 3-2 |
|
| S 3-3 |
|
| S 3-4 |
|
| S 3-5 |
|
|
| Symposium-5 “How far has the action of insulin been elucidated？” |
| May 23 (Fri.) 9:00-11:30 Room 2, Hall C |
| S 5-1 |
|
Howard Hughes Medical Institute, Division of Endocrinology, Children’s Hospital Boston, Harvard Medical School, Karp Family Research Laboratories, Boston, USA
Morris F. White |
| S 5-2 |
Diabetes and Its Complications : Insulin Action in Trouble |
Department of Biochemistry and Molecular Biology, University of Nice-Sophia Antipolis, University Hospitals, Nice, France
Emmanuel Van Obberghen |
| S 5-3 |
Role of Kruppel-like Factor 15 in Hepatic Glucose Metabolism |
Division of Diabetes, Metabolism and Endocrinology Kobe University Graduate School of Medicine, Japan
Wataru Ogawa |
| S 5-4 |
Regulation of Hepatic Insulin Sensitivity by Adiponectin |
Department of Metabolic Diseases, Graduate School of Medicine, the University of Tokyo, Japan
Kohjiro Ueki |
| S 5-5 |
Nuclear Receptor Signaling Pathways in Lipid Metabolism and Inflammation |
Howard Hughes Medical Institute and Department of Pathology and Laboratory Medicine, University of California, Los Angeles, USA
Peter Tontonoz |
|
| Symposium-6 “Inflammation and stress response in adipocytes” |
| May 23 (Fri.) 15:00-17:30 Room 2, Hall C |
| S 6-1 |
Dysregulation of G 6 PD Imbalances ROS and Metabolic Homeostasis* |
School of Biological Sciences, Institute of Molecular Biology and Genetics, Seoul National University, Seoul, Korea
Jae Bum Kim |
| S 6-2 |
|
Cellular & Molecular Physiology, Joslin Didabetes Center, Boston, MA, USA
Steven E. Shoelson |
| S 6-3 |
|
| S 6-4 |
|
| S 6-5 |
|
| S 6-6 |
Adiponectin Receptors―New Insights in the Pathogenesis of Obesity-linked Insulin Resistance and Metabolic Syndrome― |
Department of Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Japan
Toshimasa Yamauchi |
| S 6-7 |
|
|
| Symposium-7 “Mechanisms of onset of type 1 diabetes” |
| May 23 (Fri.) 9:00-11:30 Room 3, Hall B 7-1 |
| Keynote Lecture: Generation of Protective Memory Against Diabetogenic Autoimmunity in Type 1 Diabetes |
The University of Calgary, Health Sciences Centre, Canada
Pere Santamaria |
| S 7-1 |
|
| S 7-2 |
|
| S 7-3 |
|
| S 7-4 |
|
| S 7-5 |
|
|
| Symposium-8 |
| May 23 (Fri.) 15:00-17:30 Room 3, Hall B 7-1 |
| S 8-1 |
Pancreatic Islet Transplantation for the Treatment Type 1 Diabetes |
All Saints Islet Cell Laboratory, Islet Cell Transplantation Laboratory
Baylor Institute of Immunology Research, USA
Shinichi Matsumoto |
| S 8-2 |
|
| S 8-3 |
|
| S 8-4 |
|
| S 8-5 |
|
|
| Symposium-10 “Principles and practice of exercise therapy in diabetic patients” |
| May 23 (Fri.) 15:00-17:30 Room 4, Hall B 7-2 |
| S 10-1 |
Validation of AMPK as a Prevention Target for Metabolic Disease |
Department of Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Juleen R. Zierath |
| S 10-2 |
|
| S 10-3 |
|
| S 10-4 |
|
| S 10-5 |
|
| S 10-6 |
|
|
| Symposium-12 “Recent insights into the pathogenesis of diabetic retinopathy” |
| May 23 (Fri.) 9:00-11:30 Room 6, Hall D 7 |
| S 12-1 |
Contribution of Inflammation to the Early Stages of Diabetic Retinopathy |
Case Western Reserve University, USA
Timothy S. Kern |
| S 12-2 |
|
| S 12-3 |
|
| S 12-4 |
|
| S 12-5 |
|
| S 12-6 |
|
| S 12-7 |
|
|
| Symposium-16 “Diabetes-associated atherosclerosis : current findings from basic and clinical research” |
| May 24 (Sat.) 9:00-11:30 Room 3, Hall B 7-1 |
| S 16-1 |
|
| S 16-2 |
Benefits of LDL-cholesterol-lowering in Diabetes : Implications for Therapy |
Department of Medicine, University College London, University College Hospital, London, UK
John Betteridge |
| S 16-3 |
|
| S 16-4 |
|
| S 16-5 |
|
| S 16-6 |
|
|
| Symposium-18 “Latest findings on central appetite and energy regulation” |
| May 24 (Sat.) 9:00-11:30 Room 4, Hall B 7-2 |
| S 18-1 |
Forkhead, Sirtuins and the Brain |
Columbia University Diabetes and Endocrinology Research Center, New York, USA
Domenico Accili |
| S 18-2 |
Hypothalamic Integration of Hormonal Inputs |
Institute for Genetics, University of Cologne, Germany
J. Brüning |
| S 18-3 |
|
| S 18-4 |
|
| S 18-5 |
|
|
| Symposium-19 “Future perspectives on incretion therapy in diabetes” |
| May 24 (Sat.) 14:00-16:30 Room 4, Hall B 7-2 |
| S 19-1 |
Contrasting Mechanisms of Action for GLP-1 R Agonists vs. DPP-4 Inhibitors |
Banting and Best Diabetes Centre, Mount Sinai Hospital, Samuel Lunenfeld Research Institute, University of Toronto, Canada
Daniel J. Drucker |
| S 19-2 |
DPP-4 Inhibition as Treatment of Type 2 Diabetes |
Department of Clinical Sciences in Lund, Lund University, Lund, Sweden
Bo Ahrén |
| S 19-3 |
The Clinical Value of GLP-1 Analogue Therapy |
MedStar Research Institute Georgetown University School of Medical, USA
Robert E. Ratner |
| S 19-4 |
|
|
| Symposium-20 “How far have the mechanisms of insulin secretion been elucidated？” |
| May 24 (Sat.) 9:00-11:30 Room 5, Hall B 5 |
| S 20-1 |
Time and Amplitude Regulation of Insulin Secretion |
Unit of Endocrinology and Metabolism, University of Louvain, Belgium
Jean-Claude Henquin |
| S 20-2 |
How Do Beta Cells Count Their Insulin Granules？ |
Medical School University of Technology Dresden, Germany
Michele Solimena |
| S 20-3 |
|
| S 20-4 |
|
| S 20-5 |
|
|
| Symposium-21 “The pathogenesis and management of diabetic neuropathy : New developments” |
| May 24 (Sat.) 14:00-16:00 Room 6, Hall D 7 |
| S 21-1 |
Novel Mechanisms of Oxidative Stress and Peripheral Nerve Damage in Diabetes |
Pennington Biomedical Research Center, Louisiana State University, USA
Irina G. Obrosova |
| S 21-2 |
|
| S 21-3 |
|
| S 21-4 |
|
|
| Symposium-22 “Pediatric type 2 diabetes and metabolic syndrome : Current status and countermeasures” |
| May 24 (Sat.) 14:00-16:30 Room 7, Hall D 5 |
| S 22-1 |
|
| S 22-2 |
|
| S 22-3 |
|
| S 22-4 |
|
| S 22-5 |
Influence of Hypoglycemia and Metabolic Parameters on Cognitive Development in Children with Diabetes: Results from the Zurich Longitudinal Study of Childhood Diabetes |
Department of Pediatric Endocrinology & Diabetology, University Children’s Hospital, Zurich, Switzerland
Eugen J. Schoenle |
|
| Luncheon Seminar 3 |
| May 22 (Thu.) 12:00-12:50 Room 4, Hall B 7-2 |
| The Role of Incretin Hormones in Type 2 Diabetes |
| Division of Metabolism, Endocrinology and Nutrition, Dept. of Medicine, University of Washington School of Medicine |
| Steven E. Kahn |
| Luncheon Seminar 4 |
| May 22 (Thu.) 12:00-12:50 Room 5, Hall B 5 |
| Cardiovascular Risk in Type 2 Diabetes Mellitus |
| Diabetes Trials Unit, University of Oxford |
| Rury Holman |
| Luncheon Seminar 10 |
| May 22 (Thu.) 12:00-12:50 Room 11, G502 |
| International Diabetes Institute, Australia |
| Paul Zimmet |
| Luncheon Seminar 16 |
| May 23 (Fri.) 12:00-12:50 Room 3, Hall B 7-1 |
| LevemirⓇ-New Basal Insulin Analogue and its Clinical Benefits |
| Department of Clinical Science, Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany |
| Tim Heise |
| Luncheon Seminar 21 |
| May 23 (Fri.) 12:00-12:50 Room 8, Hall D 1 |
| Revolutionary Advance of Continuous Glucose Monitoring（CGM） |
| School of Podology at the University of Perugia, Italy/International Diabetes Federation（IDF） |
| Massimo Massi-Benedetti |
| Luncheon Seminar 26 |
| May 23 (Fri.) 12:00-12:50 Room 13, G602 |
| Update on CARDS and other Lipid - lowering Studies in Diabetes ; Implications for therapy |
| Department of Medicine, Royal Free and University College Medical School, University College Hospital, London, UK |
| John Betteridge |
| Luncheon Seminar 29 |
| May 24 (Sat.) 12:00-12:50 Room 2, Hall C |
| How to Treat Dyslipidemia to Prevent Cardiovascular Events - The Role of Cholesterol Absorption？ |
| Professor of Internal Medicine Chief Department of Internal Medicine Oulu University Hospital and University of Oulu, Oulu, Finland |
| Antero Kesäniemi |
| Luncheon Seminar 34 |
| May 24 (Sat.) 12:00-12:50 Room 7, Hall D 5 |
| New Treatment Strategy of Insulin Resistance, Metabolic Syndrome―Combination & Multifactorial Intervention |
| Department of Endocrinology-Diabetology, Centre Hospitalier Sud Francilien, France |
| Guillaume Charpentier |
| Luncheon Seminar 38 |
| May 24 (Sat.) 12:00-12:50 Room 11, G502 |
| Diabetes Centre for Children and Adolescents, Kinderkrankenhaus auf der Bult, Germany / German Diabetes Association |
| OlgaKordonouri |
